Clinical trials
Advanced Malignant Cancer clinical trials
Below are recruiting advanced malignant cancer clinical trials, each written for real people, not researchers. We’re tracking 1,520 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Anchorage, AlaskaAges 18 years+ - NCT07686445RecruitingPhase 1
Study of AN4035 for advanced cancers with RAS mutations
This trial tests a new drug, AN4035, for people with advanced cancers that have a RAS mutation and high levels of a protein called CEACAM5. The drug may help shrink tumors or slow their growth.
PerthAges 18 years+ - NCT05528055RecruitingPhase 1
Safety study of SCR-6920 for advanced cancers
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Jinan, ShandongAges 18–75 - NCT05947695Recruiting
Nurse-led comfort and survivorship care for advanced cancer
This study looks at whether a specialized nurse-led care plan soon after diagnosis/treatment helps people living with advanced (metastatic) cancer. It focuses on patients expected to do better than average based on certain prognosis factors.
West Islip, New YorkAges 21 years+ - NCT07811193RecruitingPhase 2
Study of new drug combined with immunotherapy for advanced bowel cancer
This trial tests a new drug (VVD-133214) combined with an existing immunotherapy (pembrolizumab) for advanced colorectal cancer that is mismatch repair deficient. It aims to see if the combination works better than pembrolizumab alone in shrinking or controlling the cancer.
Tucson, ArizonaAges 18 years+ - NCT06590506Recruiting
Wearable health tracking for advanced solid tumor treatment
This trial studies how using a wearable device and smartphone app can help monitor your health during your first cancer treatment for advanced solid tumors. You will receive a known therapy (not a placebo), and the research team will collect real-world data to improve care.
A Coruña, A Coruña/ GaliciaAges 18 years+ - NCT07680257RecruitingEarly Phase 1
CLDN18.2 CAR T cells for advanced solid tumors
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Hefei, AnhuiAges 18–75 - NCT06292208RecruitingPhase 1/Phase 2
Testing IBD0333 for advanced solid tumors or lymphoma
This trial tests an experimental drug called IBD0333 for people with advanced solid tumors or lymphoma who have run out of standard options. The drug targets a protein called 4-1BB to help your immune system fight cancer.
Jinan, ShandongAges 18–80 - NCT07224425RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called BI 3810944 for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the drug is safe and helps shrink tumors.
Louisville, KentuckyAges 18 years+ - NCT07215182RecruitingPhase 2
New PET scan method for advanced melanoma
This trial tests a new type of PET scan that may find cancer more clearly and quickly than current scans. It's for people with advanced melanoma that has spread and cannot be removed by surgery.
Herlev, Capital RegionAges 18 years+ - NCT06813079RecruitingPhase 2
Using tumor models to find your best treatment
This trial uses a personalized approach where a sample of your tumor is grown in the lab to test which drugs might work best for you. It is for people with advanced pancreatic cancer that cannot be surgically removed.
Toronto, OntarioAges 18 years+ - NCT05659732RecruitingPhase 1
Testing a new drug for advanced blood cancers
This early-phase study tests PEP07, a drug that blocks a cancer signal pathway (Checkpoint Kinase 1). It aims to see how well it works and how safely it can be given to people with certain advanced relapsed or refractory blood cancers.
Clayton, VictoriaAges 18 years+ - NCT06630351Enrolling by invitation
Meaning-centered group therapy for caregiver wellbeing
This study tests whether group therapy focused on meaning and purpose can improve the wellbeing of people caring for someone with advanced cancer or another serious illness. Caregivers will join virtual group sessions and complete questionnaires about their feelings and stress.
Jacksonville, FloridaAges 18 years+ - NCT06581432RecruitingPhase 2
Zongertinib for advanced cancers with HER2 changes
This trial tests an experimental pill called zongertinib for people with different types of advanced solid tumors that have a specific genetic change called HER2. It's a treatment option when other therapies haven't worked, and it may help shrink or slow the cancer.
Anchorage, AlaskaAges 18 years+ - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT03800693RecruitingPhase 2
Shorter vs longer oxaliplatin infusions for gut cancer
This Phase 2 study compares giving oxaliplatin by IV for 2 hours versus 6 hours, along with the standard FOLFOX6 chemotherapy. It aims to see if the shorter infusion works as well and is manageable for people with gastrointestinal cancers.
Atlanta, GeorgiaAges 18 years+ - NCT06059963Recruiting
Simple blood test for colorectal cancer screening
This study is testing a new blood test (Signal-C) to see if it can help find colorectal cancer early. You may be able to join if you are average risk and getting a routine screening colonoscopy.
Raonoke, VirginiaAges 45–84 - NCT05471856RecruitingPhase 1
Test different doses of cancer drugs with ezabenlimab
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Los Angeles, CaliforniaAges 18 years+ - NCT00804154RecruitingPhase 1
Capsaicin-like drug for severe cancer pain
This Phase 1 trial tests a new drug related to capsaicin (resiniferatoxin) to reduce severe nerve pain from advanced cancer. It is given through a small catheter near the spinal fluid space and is meant for people whose pain medicines and other options have not worked well enough.
Bethesda, MarylandAges 18–99 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+ - NCT05640830RecruitingPhase 1/Phase 2
Trastuzumab, bevacizumab, and paclitaxel for HER2-positive stomach cancer
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
SeoulAges Any age - NCT06540326RecruitingPhase 2
Second-line therapy for advanced colorectal cancer
This trial tests a combination of chemotherapy with either bevacizumab or cetuximab as a second-line treatment for advanced colorectal cancer. It aims to find which option works better for patients whose first treatment failed.
Hangzhou, ZhejiangAges 18–75 - NCT07560943RecruitingPhase 1
AI-Designed Cancer Vaccine for Advanced Solid Tumors
This trial tests a new mRNA vaccine designed by artificial intelligence to treat advanced cancers that have stopped responding to standard chemotherapy. The vaccine is personalized to each patient's tumor and aims to help the immune system fight remaining cancer cells.
Chengdu, SichuanAges 18–70
Hear when a new Advanced Malignant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant cancer?
- Yes. Clin2 currently lists 1,520 recruiting advanced malignant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.